id stringlengths 9 11 | source stringclasses 1
value | title stringlengths 15 560 | text stringlengths 2k 153k |
|---|---|---|---|
PMC12310257 | core_pubmed_pmc | From Intravenous to Subcutaneous Infliximab: the Same but Different? Real-World Evidence from a Tertiary Center | From Intravenous to Subcutaneous Infliximab: the Same but Different? Real-World Evidence from a Tertiary Center Abstract Summary Introduction. Recently, a subcutaneous formulation of infliximab was approved. The switch from intravenous infliximab to subcutaneous infliximab may improve convenience, but data on pharmacok... |
PMC9795609 | core_pubmed_pmc | Safety and microbiological activity of phage therapy in persons with cystic fibrosis colonized with Pseudomonas aeruginosa: study protocol for a phase 1b/2, multicenter, randomized, double-blind, placebo-controlled trial | Safety and microbiological activity of phage therapy in persons with cystic fibrosis colonized with Pseudomonas aeruginosa: study protocol for a phase 1b/2, multicenter, randomized, double-blind, placebo-controlled trial Abstract Background Bacteriophages (phages) are a promising anti-infective option for human disease... |
PMC9996297 | core_pubmed_pmc | Real pandemic world results of pharmacokinetic-tailored personalized prophylaxis of bleeds in Polish children and adolescents with severe hemophilia A | Real pandemic world results of pharmacokinetic-tailored personalized prophylaxis of bleeds in Polish children and adolescents with severe hemophilia A Abstract Introduction In 2020, the new nationwide protocol of prophylaxis in Polish plasma-derived FVIII (pdFVIII) previously treated patients (PTPs) with severe hemophi... |
PMC9056459 | core_pubmed_pmc | Superior Bioavailability of a Novel Curcumin Formulation in Healthy Humans Under Fasting Conditions | Superior Bioavailability of a Novel Curcumin Formulation in Healthy Humans Under Fasting Conditions Abstract Abstract Background Despite its broad range of biological activities, use of curcumin is limited because of poor bioavailability. Here we report a novel curcumin formulation, Curcuwin Ultra+ (CU+), with superior... |
PMC11535787 | core_pubmed_pmc | Toward a Clinical Decision Support System for Monitoring Therapeutic Antituberculosis Medical Drugs in Tanzania (Project TuberXpert): Protocol for an Algorithm' Development and Implementation | Toward a Clinical Decision Support System for Monitoring Therapeutic Antituberculosis Medical Drugs in Tanzania (Project TuberXpert): Protocol for an Algorithm' Development and Implementation Abstract Abstract Background The end tuberculosis (TB) strategy requires a novel patient treatment approach contrary to the one-... |
PMC12650536 | core_pubmed_pmc | First Evidence of Anti- Plasmodium vivax (Plasmodiidae): Activity of the Essential Oil and 6-Ishwarone Isolated from Piper alatipetiolatum Yunck. (Piperaceae) | First Evidence of Anti- Plasmodium vivax (Plasmodiidae): Activity of the Essential Oil and 6-Ishwarone Isolated from Piper alatipetiolatum Yunck. (Piperaceae) Abstract Abstract Background/Objectives : In the Brazilian Amazon, which accounts for over 99% of national malaria cases, 34,260 cases were reported as of August... |
PMC12409579 | core_pubmed_pmc | An LC–MS/MS Assay of Irsenontrine, a Novel Phosphodiesterase‑9 Inhibitor, in Human Plasma, Urine and Cerebrospinal Fluid for Application to Clinical Pharmacokinetic Studies | An LC–MS/MS Assay of Irsenontrine, a Novel Phosphodiesterase‑9 Inhibitor, in Human Plasma, Urine and Cerebrospinal Fluid for Application to Clinical Pharmacokinetic Studies Abstract Irsenontrine is a novel phosphodiesterase-9 inhibitor that has been developed for the treatment of cognitive dysfunction. To assess the ph... |
PMC9295372 | core_pubmed_pmc | Development of a particle swarm optimization-backpropagation artificial neural network model and effects of age and gender on pharmacokinetics study of omeprazole enteric-coated tablets in Chinese population | Development of a particle swarm optimization-backpropagation artificial neural network model and effects of age and gender on pharmacokinetics study of omeprazole enteric-coated tablets in Chinese population Abstract Abstract Background The effects of age and gender were explored on pharmacokinetics study of omeprazole... |
PMC3666662 | core_pubmed_pmc | Nanoemulsion loaded with lycobetaine–oleic acid ionic complex: physicochemical characteristics, in vitro, in vivo evaluation, and antitumor activity | Nanoemulsion loaded with lycobetaine–oleic acid ionic complex: physicochemical characteristics, in vitro, in vivo evaluation, and antitumor activity Abstract Background Intravenous injection of lycobetaine was found to show significant cytotoxic activity against (inter alia) Lewis lung carcinoma, but its therapeutic us... |
PMC6595297 | core_pubmed_pmc | Effect of CYP3A inhibitors on the pharmacokinetics of pevonedistat in patients with advanced solid tumours | Effect of CYP3A inhibitors on the pharmacokinetics of pevonedistat in patients with advanced solid tumours Abstract Aims This phase I study evaluated the effects of the moderate cytochrome P450 (CYP) 3A inhibitor fluconazole and the strong CYP3A/P‐glycoprotein (P‐gp) inhibitor itraconazole on the pharmacokinetics of th... |
PMC10366676 | core_pubmed_pmc | Bibliometric Analysis of Global Trends in Remimazolam-Related Research Over the Past 15 Years: Compared with Propofol | Bibliometric Analysis of Global Trends in Remimazolam-Related Research Over the Past 15 Years: Compared with Propofol Abstract Abstract Purpose Although remimazolam is a popular novel anesthetic, there is a lack of data in the literature about current and future trends. Therefore, the aim of this study was to explore e... |
PMC5968193 | core_pubmed_pmc | Pharmacokinetics and Pharmacodynamics of Tildipirosin Against Pasteurella multocida in a Murine Lung Infection Model | Pharmacokinetics and Pharmacodynamics of Tildipirosin Against Pasteurella multocida in a Murine Lung Infection Model Abstract Abstract Tildipirosin, a 16-membered-ring macrolide antimicrobial, has recently been approved for the treatment of swine respiratory disease and bovine respiratory disease. This macrolide is ext... |
PMC7894971 | core_pubmed_pmc | Recent Achievements and Challenges in Prolonging the Serum Half-Lives of Therapeutic IgG Antibodies Through Fc Engineering | Recent Achievements and Challenges in Prolonging the Serum Half-Lives of Therapeutic IgG Antibodies Through Fc Engineering Abstract Abstract Association of FcRn molecules to the Fc region of IgG in acidified endosomes and subsequent dissociation of the interaction in neutral pH serum enables IgG molecules to be recycle... |
PMC9427879 | core_pubmed_pmc | Pharmacokinetics of Imeglimin in Caucasian and Japanese Healthy Subjects | Pharmacokinetics of Imeglimin in Caucasian and Japanese Healthy Subjects Abstract Abstract Background Imeglimin is a first-in-class novel oral antidiabetic marketed in Japan as TWYMEEG ® to treat type 2 diabetes mellitus. Its mode of action is distinct from all other anti-hyperglycemic classes. Objective To assess the ... |
PMC12105979 | core_pubmed_pmc | Letter to the FDA Proposing Major Changes in the US Clozapine Package Insert Supported by Clozapine Experts Worldwide. Part I | Letter to the FDA Proposing Major Changes in the US Clozapine Package Insert Supported by Clozapine Experts Worldwide. Part I Abstract Abstract Purpose/Background Clozapine was approved in the United States (US) using 1989 regulations and knowledge. After 30 years, many sections of the US package insert (PI) are outdat... |
PMC7326703 | core_pubmed_pmc | Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS) | Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS) Abstract Current guidelines for smoldering multiple myeloma (SMM) recommend active monitoring until the onset of multiple myeloma (MM) before initiating ... |
PMC10819155 | core_pubmed_pmc | Use of Exposure Data to Establish Causality in Drug–Adverse Event Relationships: An Example with Desvenlafaxine | Use of Exposure Data to Establish Causality in Drug–Adverse Event Relationships: An Example with Desvenlafaxine Abstract Abstract Causality algorithms help establish relationships between drug use and adverse event (AE) occurrence. High drug exposure leads to a higher likelihood of an AE being classified as an adverse ... |
PMC11960678 | core_pubmed_pmc | Subtherapeutic Meropenem Antibiotic Exposure in Children With Septic Shock Assessed by Noncompartmental Pharmacokinetic Analysis in a Prospective Dataset | Subtherapeutic Meropenem Antibiotic Exposure in Children With Septic Shock Assessed by Noncompartmental Pharmacokinetic Analysis in a Prospective Dataset Abstract Abstract OBJECTIVES: To define meropenem plasma concentrations and pharmacodynamic exposure metrics in children with septic shock during the first 3 days of ... |
PMC11131409 | core_pubmed_pmc | Gene polymorphism as a cause of hemorrhagic complications in patients with non-valvular atrial fibrillation treated with oral vitamin K-independent anticoagulants | Gene polymorphism as a cause of hemorrhagic complications in patients with non-valvular atrial fibrillation treated with oral vitamin K-independent anticoagulants Abstract Abstract Atrial fibrillation (AF) accounts for 40% of all cardiac arrhythmias and is associated with a high risk of stroke and systemic thromboembol... |
PMC3997831 | core_pubmed_pmc | Population Pharmacokinetic Modelling of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Patients with Haemophilia B | Population Pharmacokinetic Modelling of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Patients with Haemophilia B Abstract Background and Objectives Recombinant factor IX Fc fusion protein (rFIXFc) is a clotting factor developed using monomeric Fc fusion technology to prolong the circulating half-life of factor I... |
PMC12476157 | core_pubmed_pmc | Topical Application of Everolimus Attenuates Lens-Induced Myopia Through mTORC1 Suppression | Topical Application of Everolimus Attenuates Lens-Induced Myopia Through mTORC1 Suppression Abstract Abstract Purpose The mechanistic target of rapamycin complex 1 (mTORC1) signaling has been reported to regulate lens-induced myopia (LIM) in guinea pigs. To address the challenge of delivering lipophilic mTORC1 inhibito... |
PMC4842915 | core_pubmed_pmc | Safety, pharmacokinetics and pharmacodynamics of the anti‐hepcidin Spiegelmer lexaptepid pegol in healthy subjects | Safety, pharmacokinetics and pharmacodynamics of the anti‐hepcidin Spiegelmer lexaptepid pegol in healthy subjects Abstract Abstract Background and Purpose Anaemia of chronic disease is characterized by impaired erythropoiesis due to functional iron deficiency, often caused by excessive hepcidin. Lexaptepid pegol, a pe... |
PMC5069706 | core_pubmed_pmc | A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 and 4 Weeks of Twice-Daily Ocular Trabodenoson in Adults with Ocular Hypertension or Primary Open-Angle Glaucoma | A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 and 4 Weeks of Twice-Daily Ocular Trabodenoson in Adults with Ocular Hypertension or Primary Open-Angle Glaucoma Abstract Abstract Purpose: To evaluate the safety and ocular hypotensive efficacy of 4 trabodenoson doses adm... |
PMC9008867 | core_pubmed_pmc | A phase 1 study of the safety, pharmacokinetics and pharmacodynamics of escalating doses followed by dose expansion of the selective inhibitor of nuclear export (SINE) selinexor in Asian patients with advanced or metastatic malignancies | A phase 1 study of the safety, pharmacokinetics and pharmacodynamics of escalating doses followed by dose expansion of the selective inhibitor of nuclear export (SINE) selinexor in Asian patients with advanced or metastatic malignancies Abstract Purpose: This phase 1 study aims to evaluate the tolerability and the reco... |
PMC11043204 | core_pubmed_pmc | Pharmacokinetics/pharmacodynamics of ivosidenib in advanced IDH1 -mutant cholangiocarcinoma: findings from the phase III ClarIDHy study | Pharmacokinetics/pharmacodynamics of ivosidenib in advanced IDH1 -mutant cholangiocarcinoma: findings from the phase III ClarIDHy study Abstract Abstract Purpose Report pharmacokinetic (PK)/pharmacodynamic (PD) findings from the phase III ClarIDHy study and any association between PK/PD parameters and treatment outcome... |
PMC7691962 | core_pubmed_pmc | Hydroxyurea Optimization through Precision Study (HOPS): study protocol for a randomized, multicenter trial in children with sickle cell anemia | Hydroxyurea Optimization through Precision Study (HOPS): study protocol for a randomized, multicenter trial in children with sickle cell anemia Abstract Abstract Background Sickle cell disease (SCD) is a severe and devastating hematological disorder that affects over 100,000 persons in the USA and millions worldwide. H... |
PMC6444299 | core_pubmed_pmc | Pharmacokinetic analysis for the differentiation of pituitary microadenoma subtypes through dynamic contrast-enhanced magnetic resonance imaging | Pharmacokinetic analysis for the differentiation of pituitary microadenoma subtypes through dynamic contrast-enhanced magnetic resonance imaging Abstract The value of pharmacokinetic parameters derived from dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in distinguishing pituitary microadenoma subtypes ... |
PMC8877620 | core_pubmed_pmc | Antiviral Effects of Artemisinin and Its Derivatives against SARS-CoV-2 Main Protease: Computational Evidences and Interactions with ACE2 Allelic Variants | Antiviral Effects of Artemisinin and Its Derivatives against SARS-CoV-2 Main Protease: Computational Evidences and Interactions with ACE2 Allelic Variants Abstract Fighting against the emergent coronavirus disease (COVID-19) remains a big challenge at the front of the world communities. Recent research has outlined the... |
PMC4957413 | core_pubmed_pmc | No clinically significant pharmacokinetic interactions between dolutegravir and daclatasvir in healthy adult subjects | No clinically significant pharmacokinetic interactions between dolutegravir and daclatasvir in healthy adult subjects Abstract Abstract Background Daclatasvir (DCV) is an NS5A replication complex inhibitor recently approved for chronic hepatitis C virus treatment. Methods To assess drug interactions between the HIV int... |
PMC8429405 | core_pubmed_pmc | Pharmacokinetic profile and effect on bone markers and muscle strength of two daily dosage regimens of calcifediol in osteopenic/osteoporotic postmenopausal women | Pharmacokinetic profile and effect on bone markers and muscle strength of two daily dosage regimens of calcifediol in osteopenic/osteoporotic postmenopausal women Abstract Abstract Background At present, although cholecalciferol represents the form of vitamin D of choice for the treatment of vitamin D deficiency, there... |
PMC9272739 | core_pubmed_pmc | Addressing bedaquiline treatment interruptions in the treatment of drug-resistant TB | Addressing bedaquiline treatment interruptions in the treatment of drug-resistant TB Abstract SUMMARY SETTING: The recommended dosing regimen for bedaquiline (BDQ), consisting of a 2-week loading phase (400 mg/day), followed by a maintenance phase (200 mg three times/week), might pose challenges when treatment is inter... |
PMC7034088 | core_pubmed_pmc | Effect of verapamil on the pharmacokinetics of hydroxycamptothecin and its potential mechanism | Effect of verapamil on the pharmacokinetics of hydroxycamptothecin and its potential mechanism Abstract Abstract Context Hydroxycamptothecin (HCPT) has antitumor activity in various cancers, but its poor bioavailability and efflux limit its clinical application. Verapamil has been demonstrated to improve the bioavailab... |
PMC8874425 | core_pubmed_pmc | Pharmacogenomics-Guided Pharmacotherapy in Patients with Major Depressive Disorder or Bipolar Disorder Affected by Treatment-Resistant Depressive Episodes: A Long-Term Follow-Up Study | Pharmacogenomics-Guided Pharmacotherapy in Patients with Major Depressive Disorder or Bipolar Disorder Affected by Treatment-Resistant Depressive Episodes: A Long-Term Follow-Up Study Abstract Abstract Treatment-resistant depression (TRD) reduces affected patients’ quality of life and leads to important social health c... |
PMC10251743 | core_pubmed_pmc | Disposition of a single oral dose of a cannabidiol medication in healthy cats | Disposition of a single oral dose of a cannabidiol medication in healthy cats Abstract Abstract The historical use of the marijuana plant for medicinal purposes is long. One of the historical uses has been for the treatment of epilepsy. Recently, the Food and Drug Administration has approved a highly purified cannabidi... |
PMC3828007 | core_pubmed_pmc | Pharmacometric Analyses to Support Early Development Decisions for LY2878735: A Novel Serotonin Norepinephrine Reuptake Inhibitor | Pharmacometric Analyses to Support Early Development Decisions for LY2878735: A Novel Serotonin Norepinephrine Reuptake Inhibitor Abstract Abstract LY2878735 is a novel dual serotonin (5-hydroxytryptamine (5-HT)) and norepinephrine (NE) reuptake inhibitor (SNRI) in development for chronic pain indications. In vitro pro... |
PMC8318725 | core_pubmed_pmc | Influence of SULT1A1*2 Polymorphism on Plasma Efavirenz Concentration in Thai HIV-1 Patients | Influence of SULT1A1*2 Polymorphism on Plasma Efavirenz Concentration in Thai HIV-1 Patients Abstract Abstract Purpose Plasma efavirenz (EFV) concentrations within therapeutic levels are essential to successfully treat patients suffering from human immunodeficiency virus (HIV) type 1. In addition to the drug-metabolizi... |
PMC9694039 | core_pubmed_pmc | Systems Biology Approach for Personalized Hemostasis Correction | Systems Biology Approach for Personalized Hemostasis Correction Abstract Abstract The correction of blood coagulation impairments of a bleeding or thrombotic nature employs standard protocols where the type of drug, its dose and the administration regime are stated. However, for a group of patients, such an approach ma... |
PMC11938432 | core_pubmed_pmc | Long-Acting Growth Hormone for Pediatric Growth Hormone Deficiency | Long-Acting Growth Hormone for Pediatric Growth Hormone Deficiency Abstract Abstract Long-acting growth hormone (LAGH) has the potential to improve adherence and outcomes over daily somatropin in growth hormone deficiency (GHD). Whereas daily somatropin products are molecularly identical, LAGHs are molecularly distinct... |
PMC4070280 | core_pubmed_pmc | Effect of Experimentally Induced Hepatic and Renal Failure on the Pharmacokinetics of Topiramate in Rats | Effect of Experimentally Induced Hepatic and Renal Failure on the Pharmacokinetics of Topiramate in Rats Abstract Abstract We aimed to investigate the effect of induced hepatic and renal failure on the pharmacokinetics of topiramate (TPM) in rats. Twenty-four Sprague-Dawley rats were used in this study. Renal or hepati... |
PMC10282079 | core_pubmed_pmc | Design, synthesis, in vitro anti-α-glucosidase evaluations, and computational studies of new phthalimide-phenoxy-1,2,3-triazole- N -phenyl (or benzyl) acetamides as potential anti-diabetic agents | Design, synthesis, in vitro anti-α-glucosidase evaluations, and computational studies of new phthalimide-phenoxy-1,2,3-triazole- N -phenyl (or benzyl) acetamides as potential anti-diabetic agents Abstract Abstract An important target in the treatment of type 2 diabetes is α-glucosidase. Inhibition of this enzyme led to... |
PMC7554750 | core_pubmed_pmc | Obstacles against the Marketing of Curcumin as a Drug | Obstacles against the Marketing of Curcumin as a Drug Abstract Abstract Among the extensive public and scientific interest in the use of phytochemicals to prevent or treat human diseases in recent years, natural compounds have been highly investigated to elucidate their therapeutic effect on chronic human diseases incl... |
PMC12238501 | core_pubmed_pmc | Pharmacokinetic evaluation of two oral Resveratrol formulations in a randomized, open-label, crossover study in healthy fasting subjects | Pharmacokinetic evaluation of two oral Resveratrol formulations in a randomized, open-label, crossover study in healthy fasting subjects Abstract Abstract Resveratrol is widely used in the fields of medicine and health supplements; however, its poor stability and low relative bioavailability limit its applications. Thi... |
PMC12824865 | core_pubmed_pmc | HFD-induced Alterations in Renal Tubular Oatp4c1-P-gp Transport Systems in Mice: Impact on Digoxin Renal Excretion and Gadolinium-Enhanced Radiological Manifestations | HFD-induced Alterations in Renal Tubular Oatp4c1-P-gp Transport Systems in Mice: Impact on Digoxin Renal Excretion and Gadolinium-Enhanced Radiological Manifestations Abstract Objective The clearance of digoxin in obese patients with renal impairment is reduced, leading to elevated serum concentrations and increased ri... |
PMC12706398 | core_pubmed_pmc | Rosuvastatin PBPK Modeling: Incorporating Liver Concentrations and Effects of Ethnicity, Genetic Polymorphisms, Lactone Formation, DDI and Pregnancy | Rosuvastatin PBPK Modeling: Incorporating Liver Concentrations and Effects of Ethnicity, Genetic Polymorphisms, Lactone Formation, DDI and Pregnancy Abstract ABSTRACT Rosuvastatin (RSV), a potent HMG‐CoA reductase inhibitor, is widely used for the management of hyperlipidemia and prevention of cardiovascular disease. I... |
PMC11739736 | core_pubmed_pmc | The Impact of Dexamethasone and Prednisone on Apixaban and Rivaroxaban Exposure in COVID‐19 Patients: A Physiologically Based Pharmacokinetic Modeling Study | The Impact of Dexamethasone and Prednisone on Apixaban and Rivaroxaban Exposure in COVID‐19 Patients: A Physiologically Based Pharmacokinetic Modeling Study Abstract Dexamethasone (DEX) is currently the treatment of choice for patients with oxygen‐dependent COVID‐19. It has been observed, primarily in vitro , that dexa... |
PMC12695791 | core_pubmed_pmc | Case Report: A pharmacist-led precision therapy framework for managing invasive fungal infection in CSF1R-Related leukoencephalopathy post Allo-HSCT | Case Report: A pharmacist-led precision therapy framework for managing invasive fungal infection in CSF1R-Related leukoencephalopathy post Allo-HSCT Abstract Abstract Introduction Hereditary diffuse leukoencephalopathy with spheroids (HDLS), caused by CSF1R mutations, is a rare autosomal dominant leukodystrophy charact... |
PMC8698108 | core_pubmed_pmc | Pharmacokinetic Profile of Fentanyl in the Koala ( Phascolarctos cinereus ) after Intravenous Administration, and Absorption via a Transdermal Patch | Pharmacokinetic Profile of Fentanyl in the Koala ( Phascolarctos cinereus ) after Intravenous Administration, and Absorption via a Transdermal Patch Abstract Abstract Simple Summary Koalas can be injured by cars and bushfires, and be affected by painful infectious diseases. When koalas undergo surgery to repair broken ... |
PMC10011485 | core_pubmed_pmc | Safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of WBP216, a novel IL-6 monoclonal antibody, in patients with rheumatoid arthritis: A phase Ia randomized placebo-controlled study | Safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of WBP216, a novel IL-6 monoclonal antibody, in patients with rheumatoid arthritis: A phase Ia randomized placebo-controlled study Abstract Background WBP216 is a novel human immunoglobulin G1 (IgG1) monoclonal antibody for interleukin (IL)-6. We ai... |
PMC9170314 | core_pubmed_pmc | Oral NAloxone to overcome the moRphine effect in acute COronary syndrome patients treated with TICagrelor — NARCOTIC trial | Oral NAloxone to overcome the moRphine effect in acute COronary syndrome patients treated with TICagrelor — NARCOTIC trial Abstract Abstract Background Numerous worldwide clinical trials have proven the indisputably negative influence of morphine on the pharmacokinetics and pharmacodynamics of P2Y 12 receptor inhibitor... |
PMC7297476 | core_pubmed_pmc | Comparison of Vancomycin Pharmacokinetics in Cystic Fibrosis Patients Pre and Post-lung Transplant | Comparison of Vancomycin Pharmacokinetics in Cystic Fibrosis Patients Pre and Post-lung Transplant Abstract Background: Vancomycin is commonly used to treat acute cystic fibrosis (CF) exacerbations associated with methicillin-resistant Staphylococcus aureus (MRSA). Multiple studies have demonstrated pharmacokinetic dif... |
PMC7866862 | core_pubmed_pmc | Screening, Optimization, and Bioavailability Research of Natural Deep Eutectic Solvent Extracts from Radix Pueraria | Screening, Optimization, and Bioavailability Research of Natural Deep Eutectic Solvent Extracts from Radix Pueraria Abstract Abstract Natural deep eutectic solvent (NaDES) is generally considered as a greener alternative to fossil solvent, with great potential in various areas. In the present work, 25 different NaDESs ... |
PMC8866711 | core_pubmed_pmc | Knowledge Gaps in the Pharmacokinetics of Therapeutic Proteins in Pediatric Patients | Knowledge Gaps in the Pharmacokinetics of Therapeutic Proteins in Pediatric Patients Abstract Abstract Therapeutic proteins such as monoclonal antibodies and their derivatives, fusions proteins, hormone analogs and enzymes for replacement therapy are an ever-growing mainstay in our pharmacopoeia. While a growing number... |
PMC8667943 | core_pubmed_pmc | Pharmacokinetics of ponazuril after administration of a single oral dose to green turtles ( Chelonia mydas ) | Pharmacokinetics of ponazuril after administration of a single oral dose to green turtles ( Chelonia mydas ) Abstract Abstract The coccidian protozoan, Caryospora cheloniae , has been associated with severe enteritis and encephalitis in immature farm-raised green turtles ( Chelonia mydas ) in the Cayman Islands, immatu... |
PMC9781550 | core_pubmed_pmc | Pharmacogenetic Dose Modeling Based on CYP2C19 Allelic Phenotypes | Pharmacogenetic Dose Modeling Based on CYP2C19 Allelic Phenotypes Abstract Pharmacogenetic variability in drug metabolism leads to patient vulnerability to side effects and to therapeutic failure. Our purpose was to introduce a systematic statistical methodology to estimate quantitative dose adjustments based on pharma... |
PMC10253730 | core_pubmed_pmc | Sustaining Life versus Altering Life-Saving Drugs: Insights to Explain the Paradoxical Effect of Extracorporeal Membrane Oxygenation on Drugs | Sustaining Life versus Altering Life-Saving Drugs: Insights to Explain the Paradoxical Effect of Extracorporeal Membrane Oxygenation on Drugs Abstract Abstract There has been a substantial increase in the use of extracorporeal membrane oxygenation (ECMO) support in critically ill adults. Understanding the complex chang... |
PMC3373380 | core_pubmed_pmc | Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor | Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor Abstract Background Dipeptidylpeptidase 4 (DPP4) inhibitors have clinical benefit in patients with type 2 diabetes mellitus by incr... |
PMC12473039 | core_pubmed_pmc | Interventions for Neglected Diseases Caused by Kinetoplastid Parasites: A One Health Approach to Drug Discovery, Development, and Deployment | Interventions for Neglected Diseases Caused by Kinetoplastid Parasites: A One Health Approach to Drug Discovery, Development, and Deployment Abstract Abstract Kinetoplastids are protozoa that possess a unique organelle called a kinetoplast. These include the parasites Trypanosoma cruzi , T. brucei and related African t... |
PMC5914277 | core_pubmed_pmc | Effects of Genetic Polymorphisms of CYP2B6 on the Pharmacokinetics of Bupropion and Hydroxybupropion in Healthy Chinese Subjects | Effects of Genetic Polymorphisms of CYP2B6 on the Pharmacokinetics of Bupropion and Hydroxybupropion in Healthy Chinese Subjects Abstract Abstract Background Bupropion (BUP) is an antidepressant and its pharmacological activity is mediated by its major metabolite, hydroxybupropion (HBUP). We investigated the effects of... |
PMC10224275 | core_pubmed_pmc | Application of Sucrose Acetate Isobutyrate in Development of Co-Amorphous Formulations of Tacrolimus for Bioavailability Enhancement | Application of Sucrose Acetate Isobutyrate in Development of Co-Amorphous Formulations of Tacrolimus for Bioavailability Enhancement Abstract The focus of the present work was to develop co-amorphous dispersion (CAD) formulations of tacrolimus (TAC) using sucrose acetate isobutyrate as a carrier, evaluate by in vitro a... |
PMC10459842 | core_pubmed_pmc | Evaluation of Pharmacokinetic Feasibility of Febuxostat/L-pyroglutamic Acid Cocrystals in Rats and Mice | Evaluation of Pharmacokinetic Feasibility of Febuxostat/L-pyroglutamic Acid Cocrystals in Rats and Mice Abstract Febuxostat (FBX), a selective xanthine oxidase inhibitor, belongs to BCS class II, showing low solubility and high permeability with a moderate F value (<49%). Recently, FBX/L-pyroglutamic acid cocrystal (FB... |
PMC11365876 | core_pubmed_pmc | Impact of Third-Generation Antiseizure Medications on People with Epilepsy in a Low-Income Population: The Brivaracetam Experience in a Real-World Study | Impact of Third-Generation Antiseizure Medications on People with Epilepsy in a Low-Income Population: The Brivaracetam Experience in a Real-World Study Abstract Background Third-generation antiseizure medications, such as brivaracetam, are recognized for their superior safety, tolerability, and pharmacokinetic profile... |
PMC7453069 | core_pubmed_pmc | Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin-6 | Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin-6 Abstract Abstract Background Darunavir is an anti-HIV protease inhibitor repurposed for SARS-CoV-2 treatment. Objective The aim of this study was to assess the population pharmacokinetics of darunavir... |
PMC6102747 | core_pubmed_pmc | Quercetin-3-O-β-D-glucoside decreases the bioavailability of cyclosporin A through regulation of drug metabolizing enzymes, transporters and nuclear receptors in rats | Quercetin-3-O-β-D-glucoside decreases the bioavailability of cyclosporin A through regulation of drug metabolizing enzymes, transporters and nuclear receptors in rats Abstract Quercetin is a flavonoid compound that is widely present in food and drink. Quercetin-3-O-β-D-glucoside (Q3GA) is a major metabolite of querceti... |
PMC12711370 | core_pubmed_pmc | Preparation of 18β-Glycyrrhetinic Acid Liposome and Its Therapeutic Effect on Pulmonary Arterial Hypertension | Preparation of 18β-Glycyrrhetinic Acid Liposome and Its Therapeutic Effect on Pulmonary Arterial Hypertension Abstract Abstract Purpose 18β-Glycyrrhetinic acid liposomes (18β-GA-Lips) were developed to enhance lung-specific drug delivery and optimize the therapeutic management of pulmonary arterial hypertension (PAH). ... |
PMC9794608 | core_pubmed_pmc | Pharmacokinetics and tolerability of the dual TORC1/2 inhibitor sapanisertib in combination with the MEK inhibitor trametinib in dogs | Pharmacokinetics and tolerability of the dual TORC1/2 inhibitor sapanisertib in combination with the MEK inhibitor trametinib in dogs Abstract Abstract Activation of one or both the Ras/MAPK and PI3K/Akt/mTOR signal transduction pathways are known to mediate oncogenicity of several canine and human cancers, including m... |
PMC7188703 | core_pubmed_pmc | Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma | Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma Abstract Purpose The phase Ib/II open-label study ( NCT01992653 ) evaluated the antibody-drug conjugate polatuzumab vedotin (pola) plus rituximab/obinutuzumab, cyclophosphamide, doxorubicin, and prednisone (... |
PMC10205783 | core_pubmed_pmc | Characterization and translational development of IOA-289, a novel autotaxin inhibitor for the treatment of solid tumors | Characterization and translational development of IOA-289, a novel autotaxin inhibitor for the treatment of solid tumors Abstract Abstract Background Autotaxin-lysophosphatidic acid (ATX-LPA) signaling has a predominant role in immunological and fibrotic processes, including cancer. Several ATX inhibitors and LPA recep... |
PMC6132549 | core_pubmed_pmc | Population pharmacokinetics of levodopa/carbidopa microtablets in healthy subjects and Parkinson’s disease patients | Population pharmacokinetics of levodopa/carbidopa microtablets in healthy subjects and Parkinson’s disease patients Abstract Objectives Low dose, dispersible, levodopa/carbidopa microtablets with an automatic dose dispenser have been developed to facilitate individualized levodopa treatment. The aim of this study was t... |
PMC8964862 | core_pubmed_pmc | A Randomized, Open-Label, Single-Dose Study to Assess Safety and Systemic Exposure of Triamcinolone Acetonide Extended-Release in Patients With Hip Osteoarthritis | A Randomized, Open-Label, Single-Dose Study to Assess Safety and Systemic Exposure of Triamcinolone Acetonide Extended-Release in Patients With Hip Osteoarthritis Abstract Abstract Introduction Intra-articular (IA) corticosteroids, including triamcinolone acetonide (TA), are a recommended treatment for hip osteoarthrit... |
PMC10725259 | core_pubmed_pmc | Physiologically‐based pharmacokinetic model to predict doxorubicin and paclitaxel exposure in infants through breast milk | Physiologically‐based pharmacokinetic model to predict doxorubicin and paclitaxel exposure in infants through breast milk Abstract Abstract Limited information is available concerning infant exposure and safety when breastfed by mothers receiving chemotherapy. Whereas defining distribution to breast milk is important t... |
PMC11794604 | core_pubmed_pmc | Development of an mPBPK machine learning framework for early target pharmacology assessment of biotherapeutics | Development of an mPBPK machine learning framework for early target pharmacology assessment of biotherapeutics Abstract Development of antibodies often begins with the assessment and optimization of their physicochemical properties, and their efficient engagement with the target of interest. Decisions at the early opti... |
PMC2959074 | core_pubmed_pmc | Pharmacokinetics of artemether and dihydroartemisinin in healthy Pakistani male volunteers treated with artemether-lumefantrine | Pharmacokinetics of artemether and dihydroartemisinin in healthy Pakistani male volunteers treated with artemether-lumefantrine Abstract Background Artemether-lumefantrine is one of the most widely used anti-malarial drug combinations in the world with excellent tolerability and cure rates in adult and paediatric patie... |
PMC9890763 | core_pubmed_pmc | Pharmacokinetics of a microdosed cocktail of three direct oral anticoagulants in children with congenital heart defects: study protocol for a single-centre clinical trial (DOAC-Child) | Pharmacokinetics of a microdosed cocktail of three direct oral anticoagulants in children with congenital heart defects: study protocol for a single-centre clinical trial (DOAC-Child) Abstract Abstract Introduction Direct oral anticoagulants (DOACs) are direct inhibitors of coagulation factor Xa and are frequently used... |
PMC5986181 | core_pubmed_pmc | Toxicity Testing in the 21 st Century Beyond Environmental Chemicals | Toxicity Testing in the 21 st Century Beyond Environmental Chemicals Abstract Summary After the publication of the report titled Toxicity Testing in the 21 st Century – A Vision and a Strategy , many initiatives started to foster a major paradigm shift for toxicity testing – from apical endpoints in animal-based tests ... |
PMC8572678 | core_pubmed_pmc | Quantitative determination of D 4 -cystine in mice using LC-MS/MS and its application to the assessment of pharmacokinetics and bioavailability | Quantitative determination of D 4 -cystine in mice using LC-MS/MS and its application to the assessment of pharmacokinetics and bioavailability Abstract Abstract Cystine is the primary source material for the synthesis of glutathione. However, the pharmacokinetics and tissue distribution of cystine are largely unknown.... |
PMC8775965 | core_pubmed_pmc | Dynamic Contrast-Enhanced Magnetic Resonance Imaging for the Prediction of Monoclonal Antibody Tumor Disposition | Dynamic Contrast-Enhanced Magnetic Resonance Imaging for the Prediction of Monoclonal Antibody Tumor Disposition Abstract The prediction of monoclonal antibody (mAb) disposition within solid tumors for individual patients is difficult due to inter-patient variability in tumor physiology. Improved a priori prediction of... |
PMC6004234 | core_pubmed_pmc | Suboptimal Antituberculosis Drug Concentrations and Outcomes in Small and HIV‐Coinfected Children in India: Recommendations for Dose Modifications | Suboptimal Antituberculosis Drug Concentrations and Outcomes in Small and HIV‐Coinfected Children in India: Recommendations for Dose Modifications Abstract Abstract This work aimed to evaluate the once‐daily antituberculosis treatment as recommended by the new Indian pediatric guidelines. Isoniazid, rifampin, and pyraz... |
PMC7682474 | core_pubmed_pmc | Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma | Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma Abstract Abstract Background To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of eftilagimod alpha (efti), a soluble lymphocyte activation gene-3 protein, in combi... |
PMC8598183 | core_pubmed_pmc | Treating insomnia symptoms with medicinal cannabis: a randomized, crossover trial of the efficacy of a cannabinoid medicine compared with placebo | Treating insomnia symptoms with medicinal cannabis: a randomized, crossover trial of the efficacy of a cannabinoid medicine compared with placebo Abstract Abstract Study Objectives This randomized, double-blind, placebo-controlled, crossover study was conducted to evaluate the safety and efficacy of 2 weeks of nightly ... |
PMC5816749 | core_pubmed_pmc | Genetic Parameter Estimates for Metabolizing Two Common Pharmaceuticals in Swine | Genetic Parameter Estimates for Metabolizing Two Common Pharmaceuticals in Swine Abstract In livestock, the regulation of drugs used to treat livestock has received increased attention and it is currently unknown how much of the phenotypic variation in drug metabolism is due to the genetics of an animal. Therefore, the... |
PMC7511285 | core_pubmed_pmc | Rectal Omeprazole in Infants With Gastroesophageal Reflux Disease: A Randomized Pilot Trial | Rectal Omeprazole in Infants With Gastroesophageal Reflux Disease: A Randomized Pilot Trial Abstract Abstract Background and Objective Omeprazole is a proton pump inhibitor that is used in acid suppression therapy in infants. Infants cannot swallow the oral tablets or capsules. Since, infants require a non-standard dos... |
PMC11237172 | core_pubmed_pmc | No dose adjustment of metformin or substrates of organic cation transporters (OCT)1 and OCT2 and multidrug and toxin extrusion protein (MATE)1/2K with fostemsavir coadministration based on modeling approaches | No dose adjustment of metformin or substrates of organic cation transporters (OCT)1 and OCT2 and multidrug and toxin extrusion protein (MATE)1/2K with fostemsavir coadministration based on modeling approaches Abstract Abstract Fostemsavir is an approved gp120‐directed attachment inhibitor and prodrug for the treatment ... |
PMC5465826 | core_pubmed_pmc | Stereospecific pharmacokinetic characterization of liquiritigenin in the rat | Stereospecific pharmacokinetic characterization of liquiritigenin in the rat Abstract Liquiritigenin is a chiral flavonoid present in licorice and other medicinal plants. The nature of its biological fate with respect to the individual enantiomers has not been examined. In this study, we characterize, for the first tim... |
PMC11912748 | core_pubmed_pmc | Image-Guided Monitoring of Mitochondria and Blood–Brain Barrier Dysfunction in Amyotrophic Lateral Sclerosis Mice | Image-Guided Monitoring of Mitochondria and Blood–Brain Barrier Dysfunction in Amyotrophic Lateral Sclerosis Mice Abstract Abstract Early detection of amyotrophic lateral sclerosis (ALS) progression is critical for improving disease management and therapeutic outcomes. However, the clinical heterogeneity and variabilit... |
PMC12706417 | core_pubmed_pmc | A Combined Modeling Approach to Predict the Effect of Gastric Emptying Delay on the Pharmacokinetics of Small Molecules | A Combined Modeling Approach to Predict the Effect of Gastric Emptying Delay on the Pharmacokinetics of Small Molecules Abstract ABSTRACT Dulaglutide, a long‐acting glucagon‐like peptide‐1 (GLP‐1) receptor agonist, is approved for improving glycemic control and reducing cardiovascular risks in patients with type 2 diab... |
PMC11374901 | core_pubmed_pmc | Quantifying trade-offs between therapeutic efficacy and resistance dissemination for enrofloxacin dose regimens in cattle | Quantifying trade-offs between therapeutic efficacy and resistance dissemination for enrofloxacin dose regimens in cattle Abstract Abstract The use of antimicrobial drugs in food-producing animals contributes to the selection pressure on pathogenic and commensal bacteria to become resistant. This study aims to evaluate... |
PMC7049277 | core_pubmed_pmc | Contribution of Trough Concentration Data in the Evaluation of Multiple-Dose Pharmacokinetics for Drugs with Delayed Distributional Equilibrium and Long Half-Life | Contribution of Trough Concentration Data in the Evaluation of Multiple-Dose Pharmacokinetics for Drugs with Delayed Distributional Equilibrium and Long Half-Life Abstract Abstract Purpose The performance of “trough sampling before reaching steady-state” and “serial sampling beyond the interval between steady-state” in... |
PMC7759869 | core_pubmed_pmc | Identification of Enzymes Oxidizing the Tyrosine Kinase Inhibitor Cabozantinib: Cabozantinib Is Predominantly Oxidized by CYP3A4 and Its Oxidation Is Stimulated by cyt b 5 Activity | Identification of Enzymes Oxidizing the Tyrosine Kinase Inhibitor Cabozantinib: Cabozantinib Is Predominantly Oxidized by CYP3A4 and Its Oxidation Is Stimulated by cyt b 5 Activity Abstract Abstract Herein, the in vitro metabolism of tyrosine kinase inhibitor cabozantinib, the drug used for the treatment of metastatic ... |
PMC6195370 | core_pubmed_pmc | The clinical relevance of progestogens in hormonal contraception: Present status and future developments | The clinical relevance of progestogens in hormonal contraception: Present status and future developments Abstract Abstract The contraceptive pill is an effective and very safe method to control pregnancies. It was developed 60 years ago, and despite, that the composition has been the same since it was first developed (... |
PMC4752501 | core_pubmed_pmc | EPICE-HIV: An Epidemiologic Cost-Effectiveness Model for HIV Treatment | EPICE-HIV: An Epidemiologic Cost-Effectiveness Model for HIV Treatment Abstract The goal of this research was to establish a new and innovative framework for cost-effectiveness modeling of HIV-1 treatment, simultaneously considering both clinical and epidemiological outcomes. EPICE-HIV is a multi-paradigm model based o... |
PMC9794590 | core_pubmed_pmc | Physiologically based pharmacokinetic modelling and simulation to predict the plasma concentration profile of schaftoside after oral administration of total flavonoids of Desmodium styracifolium | Physiologically based pharmacokinetic modelling and simulation to predict the plasma concentration profile of schaftoside after oral administration of total flavonoids of Desmodium styracifolium Abstract Abstract Introduction: The total flavonoids of Desmodium styracifolium (TFDS) are the flavonoid extracts purified fr... |
PMC4203514 | core_pubmed_pmc | Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma | Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma Abstract Blocking autophagy with hydroxychloroquine (HCQ) augments cell death associated with alkylating chemotherapy in preclinical models. This phase I study evaluated the maximum tolerated dose (MTD... |
PMC2914736 | core_pubmed_pmc | First administration to man of Org 25435, an intravenous anaesthetic: A Phase 1 Clinical Trial | First administration to man of Org 25435, an intravenous anaesthetic: A Phase 1 Clinical Trial Abstract Background Org 25435 is a new water-soluble alpha-amino acid ester intravenous anaesthetic which proved satisfactory in animal studies. This study aimed to assess the safety, tolerability and efficacy of Org 25435 an... |
PMC9541965 | core_pubmed_pmc | Kinetics of 5% and 20% albumin: A controlled crossover trial in volunteers | Kinetics of 5% and 20% albumin: A controlled crossover trial in volunteers Abstract Abstract Background Albumin for intravenous infusion is marketed in two concentrations, 20% and 5%, but how they compare with regard to plasma volume expansion over time is unclear. Methods In a prospective crossover study, 12 volunteer... |
PMC5193001 | core_pubmed_pmc | Modeling of Large Pharmacokinetic Data Using Nonlinear Mixed‐Effects: A Paradigm Shift in Veterinary Pharmacology. A Case Study With Robenacoxib in Cats | Modeling of Large Pharmacokinetic Data Using Nonlinear Mixed‐Effects: A Paradigm Shift in Veterinary Pharmacology. A Case Study With Robenacoxib in Cats Abstract Abstract The objective of this study was to model the pharmacokinetics (PKs) of robenacoxib in cats using a nonlinear mixed‐effects (NLME) approach, leveragin... |
PMC9403128 | core_pubmed_pmc | Drosophila melanogaster diabetes models and its usage in the research of anti-diabetes management with traditional Chinese medicines | Drosophila melanogaster diabetes models and its usage in the research of anti-diabetes management with traditional Chinese medicines Abstract Abstract The prevalence of diabetes mellitus (DM) is increasing rapidly worldwide, but the underlying molecular mechanisms of disease development have not been elucidated, and th... |
PMC6856490 | core_pubmed_pmc | Population Pharmacokinetics of Sarilumab in Patients with Rheumatoid Arthritis | Population Pharmacokinetics of Sarilumab in Patients with Rheumatoid Arthritis Abstract Background and Objective Sarilumab binds to the interleukin-6 receptor with high affinity, inhibiting cis and trans signaling by interleukin-6. Sarilumab has demonstrated efficacy and safety in patients with rheumatoid arthritis. Th... |
PMC9664624 | core_pubmed_pmc | Dual-labeled nanoparticles based on small extracellular vesicles for tumor detection | Dual-labeled nanoparticles based on small extracellular vesicles for tumor detection Abstract Abstract Background Small extracellular vesicles (sEVs) are emerging natural nanoplatforms in cancer diagnosis and therapy, through the incorporation of signal components or drugs in their structure. However, for their transla... |
PMC8752106 | core_pubmed_pmc | Pharmacokinetic‐pharmacodynamic modelling of the anti‐FcRn monoclonal antibody rozanolixizumab: Translation from preclinical stages to the clinic | Pharmacokinetic‐pharmacodynamic modelling of the anti‐FcRn monoclonal antibody rozanolixizumab: Translation from preclinical stages to the clinic Abstract Abstract Rozanolixizumab is a fully humanized high‐affinity anti‐human neonatal Fc receptor (FcRn) monoclonal antibody (mAb) that accelerates the removal of circulat... |
PMC12527224 | core_pubmed_pmc | Hit-to-Lead Optimization of Acetazolamide-Based Bacterial Carbonic Anhydrase Inhibitors with Efficacy In Vivo for Treatment of Vancomycin-Resistant Enterococci Septicemia | Hit-to-Lead Optimization of Acetazolamide-Based Bacterial Carbonic Anhydrase Inhibitors with Efficacy In Vivo for Treatment of Vancomycin-Resistant Enterococci Septicemia Abstract Abstract As one of the leading causes of hospital-acquired infections reported by the National Healthcare Safety Network, vancomycin-resista... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.